信立泰：关于SAL0150药品临床试验申请获得受理的公告

Core Viewpoint - The company, Xinlitai, announced that its self-developed innovative drug SAL0150 has received acceptance for clinical trial application by the National Medical Products Administration, targeting treatment for type 2 diabetes and its complications, as well as obesity or overweight, with a potential for once-a-week oral administration [1] Group 1 - The drug SAL0150 is an oral long-acting formulation [1] - The intended use of SAL0150 includes treatment for type 2 diabetes and its complications, as well as obesity or overweight [1] - The drug has the potential to be administered once a week, which may improve patient compliance [1]